(Q43047552)

12 November 2017

Adenovirus-mediated gene transfer of interferon alpha inhibits hepatitis C virus replication in hepatocytes (English)

1 reference

12 November 2017

1 reference

1 reference

Koichi Suzuki

1

1 reference

12 November 2017

Kazunori Aoki

2

1 reference

12 November 2017

Shumpei Ohnami

3

1 reference

12 November 2017

Kimiko Yoshida

4

1 reference

12 November 2017

Teruhisa Kazui

5

1 reference

12 November 2017

Nobuyuki Kato

6

1 reference

12 November 2017

Kazuaki Inoue

7

1 reference

12 November 2017

Michinori Kohara

8

1 reference

12 November 2017

Teruhiko Yoshida

9

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

Biochemical and Biophysical Research Communications

12 November 2017

1 reference

12 November 2017

307

1 reference

12 November 2017

4

1 reference

12 November 2017

814-819

1 reference

The treatment of chronic viral hepatitis

12 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901255-5

Therapy of hepatitis C: patients with cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901255-5

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901255-5

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901255-5

Adenovirus-mediated gene transfer of interferon α improves dimethylnitrosamine-induced liver cirrhosis in rat model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901255-5

Hepatitis C virus NS4A and NS4B proteins suppress translation in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901255-5

In vitro models for hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901255-5

Human hepatocyte clonal cell lines that support persistent replication of hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901255-5

Cell lines from non-neoplastic liver and hepatocellular carcinoma tissue from a single patient.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901255-5

Replication of hepatitis C virus in cultured non-neoplastic human hepatocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901255-5

Susceptibility of human T-lymphotropic virus type I infected cell line MT-2 to hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901255-5

Restricted expression of an adenoviral vector encoding Fas ligand (CD95L) enhances safety for cancer gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901255-5

Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901255-5

Efficient selection for high-expression transfectants with a novel eukaryotic vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901255-5

Real-time detection system for quantification of hepatitis C virus genome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901255-5

Comparison of hypervariable regions (HVR1 and HVR2) in positive- and negative-stranded hepatitis C virus RNA in cancerous and non-cancerous liver tissue, peripheral blood mononuclear cells and serum from a patient with hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901255-5

Genetic alterations of the putative envelope proteins encoding region of the hepatitis C virus in the progression to relapsed phase from acute hepatitis: humoral immune response to hypervariable region 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901255-5

Selective transmission of hepatitis C virus in vivo and in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901255-5

Genetic analysis of the hepatitis C virus (HCV) genome from HCV-infected human T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901255-5

In vitro migratory potential of rat quiescent hepatic stellate cells and its augmentation by cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901255-5

Interferons and their actions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901255-5

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901255-5

Effect of alpha interferon on the hepatitis C virus replicon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901255-5

Alpha Interferon Inhibits Hepatitis C Virus Replication in Primary Human Hepatocytes Infected In Vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901255-5

Randomised trial of lymphoblastoid alpha-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901255-5

Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901255-5

Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901255-5

Effects of long-term administration of interferon α in two models of liver fibrosis in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901255-5

Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901255-5

Histological outcome in interferon alpha-2b treated patients with chronic posttransfusion non-A, non-B hepatitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901255-5

Changes of liver fibrosis in chronic hepatitis C patients with no response to interferon-alpha therapy: including quantitative assessment by a morphometric method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901255-5

Genetic drift in hypervariable region 1 of the viral genome in persistent hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901255-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-291X(03)01255-5

1 reference

12 November 2017

1 reference